Overview
Updated 14 Jul 2026
Melissa Alsina, MD, is Associate Professor of Medicine, Blood and Marrow Transplant Program at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. The public record shows 561 publications with 18,343 citations (h-index 64), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 12 companies, 1 NIH-funded awards (2000–2000).
- Most recent indexed publication: 2026 · Cancer research
- Top research focus: Multiple Myeloma Research and Treatments
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 168.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
InvestigatorPhase 1RecruitingNCT07250087 - Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
InvestigatorPhase 2RecruitingNCT06947083 - Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
InvestigatorPhase 2TerminatedNCT03411031
Industry payments
Updated 14 Jul 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year20252 payments
- Janssen Biotech, Inc.Program year20254 payments
- Kite Pharma, Inc.Program year20251 payment
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2000–2000 per NIH RePORTER. The latest:
Congress activity
Updated 14 Jul 2026
129 congress contributions (2005–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- AI-enabled multimodal adjudication of revised IMWG progression after BCMA CAR-T.
ASCO Annual Meeting
ASCO2026Co-author - Impact of autoimmune disease on toxicity and outcomes after idecabtagene vicleucel in patients with multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Journal of clinical oncology
2025 - Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.
Future oncology (London, England)
2025
Most-cited worksby citation count (OpenAlex)
- 01A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 02
- 03
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
12902 USF Magnolia Drive, Tampa, FL 33612
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- MD
University of Puerto Rico School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Residency
Internal Medicine, San Juan Veterans Administration Hospital (VA Caribbean Healthcare System)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Fellowship
Hematology, San Juan City Hospital, Puerto Rico
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Fellowship
Medical Oncology/Hematology, University of Texas Health Science Center at San Antonio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Board Certified
Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership rolesjournal and society appointments
- Member
NCCN Myeloma Guidelines Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Member
NCI Myeloma Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Member
International Myeloma Working Group (IMWG)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myeloma.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Secondary affiliationsappointments beyond the home institution
- Formerly Co-Director
Myeloma Bone Disease Program Clinic, UT Health Science Center at San Antonio
1999verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Formerly Assistant Professor of Medicine
South Texas Veterans Health Care System, San Antonio, TX
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ecancer.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- Contributing author
Targeted Oncology (myeloma/immunotherapy commentary)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/melissa-alsina-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Melissa-Alsina-39717659
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
cancernetwork.com/authors/melissa-alsina-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - Other
targetedonc.com/authors/melissa-alsina-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Rami Komrokji, MD
Moffitt Cancer Center
- 1,527
- publications
- 69
- h-index
- 14
- trials
Alberto Chiappori, MD
Moffitt Cancer Center
- 257
- publications
- 48
- h-index
- 13
- trials
Richard Kim, MD
Moffitt Cancer Center
- 348
- publications
- 37
- h-index
- 19
- trials